British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
Continue reading...
TH
Source
This article was originally published by The Guardian and written by Julia Kollewe.
Read original article on The Guardian